- Home
- CNTA vs ETV Comparison
CNTA vs ETV Comparison
Compare CNTA & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- ETV
- Stock Information
- Founded
- CNTA 2020
- ETV 2005
- Country
- CNTA United Kingdom
- ETV United States
- Employees
- CNTA N/A
- ETV N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- ETV Investment Managers
- Sector
- CNTA Health Care
- ETV Finance
- Exchange
- CNTA Nasdaq
- ETV Nasdaq
- Market Cap
- CNTA 1.6B
- ETV 1.6B
- IPO Year
- CNTA 2021
- ETV N/A
- Fundamental
- Price
- CNTA $14.29
- ETV $13.91
- Analyst Decision
- CNTA Strong Buy
- ETV
- Analyst Count
- CNTA 10
- ETV 0
- Target Price
- CNTA $28.78
- ETV N/A
- AVG Volume (30 Days)
- CNTA 980.2K
- ETV 252.5K
- Earning Date
- CNTA 08-12-2025
- ETV 01-01-0001
- Dividend Yield
- CNTA N/A
- ETV 8.75%
- EPS Growth
- CNTA N/A
- ETV N/A
- EPS
- CNTA N/A
- ETV N/A
- Revenue
- CNTA $15,000,000.00
- ETV N/A
- Revenue This Year
- CNTA N/A
- ETV N/A
- Revenue Next Year
- CNTA N/A
- ETV N/A
- P/E Ratio
- CNTA N/A
- ETV N/A
- Revenue Growth
- CNTA 118.88
- ETV N/A
- 52 Week Low
- CNTA $9.00
- ETV $11.05
- 52 Week High
- CNTA $19.09
- ETV $13.50
- Technical
- Relative Strength Index (RSI)
- CNTA 61.38
- ETV 63.53
- Support Level
- CNTA $13.22
- ETV $13.73
- Resistance Level
- CNTA $14.74
- ETV $13.93
- Average True Range (ATR)
- CNTA 0.73
- ETV 0.12
- MACD
- CNTA 0.14
- ETV 0.01
- Stochastic Oscillator
- CNTA 85.11
- ETV 86.07
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.